Posting of Annual Report & Notice of AGM

2^nd May 2016

EKF Diagnostics Holdings plc (AIM: EKF), the point-of-care business, confirms that the Annual Report and Accounts for the year ended 31 December 2015, the Notice of the Annual General Meeting and a Form of Proxy are now available on the Company's website: www.ekfdiagnostics.com

The AGM is to be held on Thursday 2 June 2016 at 11am at the offices of Harwood Capital LLP, 6 Stratton Street, Mayfair, London W1J 8LD.

The 2015 Annual Report and Accounts and other documents will be posted to shareholders on Monday, 9 May 2016.

EKF Diagnostics Holdings plc Christopher Mills, Non-Executive Chairman Julian Baines, CEO Richard Evans, Finance Director and COO	00 44 29 2071 0570
Panmure Gordon (UK) Limited Robert Naylor Paul Fincham	00 44 20 7886 2500
Walbrook PR Limited Paul McManus Lianne Cawthorne	00 44 20 7933 8780 or ekf@walbrookpr.com 00 44 7980 541 893 00 44 7584 391 303

Back to Listing

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

EKF Publishes Guide to Good Capillary Blood Sampling

Incorrect capillary blood sampling is most common reason for inaccurate POC hemoglobin results.

Quo Lab takes off in Italy

In a drive to improve management of diabetes, a campaign was launched in Italy to raise awareness introduction of EKF's Quo Lab system in all hospitals of the the Lazio region.

New UltraCrit Training Video

EKF secures FDA clearance for DiaSpect Tm POC hemoglobin analyzer

Easy to use, reagent-free analyzer cleared for use in POC & CLIA waived settings.

Shelf-life extension for DiaSpect HBT Controls

We are pleased to announce that the DiaSpect HBT controls for the DiaSpect Tm have been modified to enhance shelf-life to 11 months from date of production. The new controls will have a more ‘blood-like’ look and feel but remain classified as a non-hazardous product.